Valbiotis SA (FR:ALVAL) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Valbiotis announced the success of its INSIGHT clinical study, demonstrating that TOTUM•854 significantly reduces systolic blood pressure in individuals with untreated mild hypertension. This success marks TOTUM•854 as a promising non-drug solution for cardiovascular disease prevention, aligning with Valbiotis’ mission to improve health through innovative plant-based products.
For further insights into FR:ALVAL stock, check out TipRanks’ Stock Analysis page.